King's College London develops ERB antibiotics
Analysis based on 7 articles · First reported May 29, 2026 · Last updated May 29, 2026
This breakthrough could significantly impact pharmaceutical companies involved in antibiotic development, potentially leading to new drug pipelines and revitalizing existing ones. It offers hope for combating the growing global threat of antibiotic resistance, which could reduce healthcare costs and improve public health outcomes, positively affecting the healthcare sector.
Researchers at King s College London, led by Professor Khondaker Miraz Rahman and in collaboration with Professor Mark Sutton from the United Kingdom — UK Health Security Agency, have developed a new approach called 'Efflux Resistance Breaker' (ERB) for designing antibiotics. This method chemically redesigns antibiotics to prevent bacteria from pumping them out of cells, thereby restoring their effectiveness against drug-resistant infections. The study, published in the Journal of Medicinal Chemistry, provides a proof of concept for building resistance-breaking properties directly into antibiotic molecules. This innovation aims to discover new treatments and revive existing antibiotics that have lost efficacy due to bacterial evolution, addressing the critical global threat of antimicrobial resistance highlighted by the World Health Organization.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard